5 results on '"Patel, Raihaan"'
Search Results
2. Healthy versus Entorhinal Cortical Atrophy Identification in Asymptomatic APOE4 Carriers at Risk for Alzheimer's Disease.
- Author
-
Kyoko Konishi, Joober, Ridha, Poirier, Judes, MacDonald, Kathleen, Chakravarty, Mallar, Patel, Raihaan, Breitner, John, Bohbot, Véronique D., and Konishi, Kyoko
- Subjects
ALZHEIMER'S disease diagnosis ,EARLY diagnosis ,APOLIPOPROTEIN E gene ,GRAY matter (Nerve tissue) ,ATROPHY ,MAGNETIC resonance imaging of the brain ,ENTORHINAL cortex ,ALLELES ,ALZHEIMER'S disease ,APOLIPOPROTEINS ,COMPARATIVE studies ,HIPPOCAMPUS (Brain) ,MAGNETIC resonance imaging ,RESEARCH methodology ,MEDICAL cooperation ,MEMORY ,RESEARCH ,RESEARCH funding ,TEMPORAL lobe ,EVALUATION research ,CASE-control method ,GENETIC carriers - Abstract
Early detection of Alzheimer's disease (AD) has been challenging as current biomarkers are invasive and costly. Strong predictors of future AD diagnosis include lower volume of the hippocampus and entorhinal cortex, as well as the ɛ4 allele of the Apolipoprotein E gene (APOE) gene. Therefore, studying functions that are critically mediated by the hippocampus and entorhinal cortex, such as spatial memory, in APOE ɛ4 allele carriers, may be key to the identification of individuals at risk of AD, prior to the manifestation of cognitive impairments. Using a virtual navigation task developed in-house, specifically designed to assess spatial versus non-spatial strategies, the current study is the first to differentiate functional and structural differences within APOE ɛ4 allele carriers. APOE ɛ4 allele carriers that predominantly use non-spatial strategies have decreased fMRI activity in the hippocampus and increased atrophy in the hippocampus, entorhinal cortex, and fimbria compared to APOE ɛ4 allele carriers who use spatial strategies. In contrast, APOE ɛ4 allele carriers who use spatial strategies have grey matter levels comparable to non-APOE ɛ4 allele carriers. Furthermore, in a leave-one-out analysis, grey matter in the entorhinal cortex could predict navigational strategy with 92% accuracy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
3. The Effects of Cortical Hypometabolism and Hippocampal Atrophy on Clinical Trajectories in Mild Cognitive Impairment with Suspected Non-Alzheimer's Pathology: A Brief Report.
- Author
-
Chung, Jun Ku, Plitman, Eric, Nakajima, Shinichiro, Caravaggio, Fernando, Shinagawa, Shunichiro, Iwata, Yusuke, Gerretsen, Philip, Kim, Julia, Takeuchi, Hiroyoshi, Patel, Raihaan, Chakravarty, M Mallar, Strafella, Antonio, Graff-Guerrero, Ariel, and Alzheimer’s Disease Neuroimaging Initiative
- Abstract
The clinical and structural trajectories of suspected non-Alzheimer' pathology (SNAP) remain elusive due to its heterogeneous etiology. Baseline and longitudinal clinical (global cognition, daily functioning, symptoms of dementia, and learning memory) and hippocampal volume trajectories over two years were compared between patients with amnestic mild cognitive impairment (aMCI) with SNAP with reduced hippocampal volumes (SNAP+HIPPO) and aMCI patients with SNAP without reduced hippocampal volumes. SNAP+HIPPO showed overall worse baseline cognitive functions. Longitudinally, SNAP+HIPPO showed faster deterioration of clinical symptoms of dementia. Having both hippocampal atrophy and cortical hypometabolism without amyloid pathology may exacerbate symptoms of dementia in aMCI. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
4. Hippocampal and Clinical Trajectories of Mild Cognitive Impairment with Suspected Non-Alzheimer's Disease Pathology.
- Author
-
Jun Ku Chung, Eric Plitman, Shinichiro Nakajima, Fernando Caravaggio, Yusuke Iwata, Gerretsen, Philip, Kim, Julia, Hiroyoshi Takeuchi, Shunichiro Shinagawa, Patel, Raihaan, Chakravarty, M. Mallar, Graff-Guerrero, Ariel, Chung, Jun Ku, Plitman, Eric, Nakajima, Shinichiro, Caravaggio, Fernando, Iwata, Yusuke, Takeuchi, Hiroyoshi, Shinagawa, Shunichiro, and Alzheimer’s Disease Neuroimaging Initiative
- Subjects
MILD cognitive impairment ,NEURODEGENERATION ,AMYLOID ,HIPPOCAMPUS (Brain) ,PATHOLOGY ,PROTEIN metabolism ,ALZHEIMER'S disease ,ANTHROPOMETRY ,APOLIPOPROTEINS ,COGNITION ,LONGITUDINAL method ,MAGNETIC resonance imaging ,POSITRON emission tomography ,ACTIVITIES of daily living ,DISEASE progression - Abstract
Suspected non-Alzheimer's disease pathology (SNAP) characterizes individuals showing neurodegeneration (e.g., hypometabolism) without amyloid-β (Aβ). Findings from previous studies regarding clinical and structural trajectories of SNAP are inconsistent. Using data from the Alzheimer's Disease Neuroimaging Initiative, patients with amnestic mild cognitive impairment (MCI) were categorized into four groups: amyloid positive with hypometabolism (Aβ+ND+), amyloid only (Aβ+ND-), neither amyloid nor hypometabolism (Aβ-ND-), and SNAP (Aβ-ND+). Aβ+ND+(n = 33), Aβ+ND-(n = 32), and Aβ-ND-(n = 36) were matched to SNAP for age, gender, apolipoprotein E4 (apoE4) genotype, and scores on the Montreal Cognitive Assessment. Elderly controls (n = 40) were also matched to SNAP for age, gender, and apoE4 genotype. Longitudinal changes were compared across groups in terms of hippocampal volume, clinical symptoms, daily functioning, and cognitive functioning over a 2-year period. At baseline, no difference in cognition and functioning was observed between SNAP and Aβ+groups. SNAP showed worse clinical symptoms and impaired functioning at baseline compared to Aβ-ND-and controls. Two years of follow-up showed no differences in hippocampal volume changes between SNAP and any of the comparison groups. SNAP showed worse functional deterioration in comparison to Aβ-ND-and controls. However, Aβ+ND+ showed more severe changes in clinical symptoms in comparison to SNAP. Thus, patients with MCI and SNAP showed 1) more severe functional deterioration compared to Aβ-ND-and controls, 2) no differences with Aβ+ND-, and 3) less cognitive deterioration than Aβ+ND+. Future studies should investigate what causes SNAP, which is different from typical AD pathology and biomarker cascades. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
5. Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment.
- Author
-
Jun Ku Chung, Plitman, Eric, Shinichiro Nakajima, Mallar Chakravarty, M., Caravaggio, Fernando, Hiroyoshi Takeuchi, Gerretsen, Philip, Yusuke Iwata, Patel, Raihaan, Mulsant, Benoit H., Graff-Guerrero, Ariel, Chung, Jun Ku, Nakajima, Shinichiro, Chakravarty, M Mallar, Takeuchi, Hiroyoshi, and Iwata, Yusuke
- Subjects
HIPPOCAMPUS diseases ,MILD cognitive impairment ,DIAGNOSIS of dementia ,DIAGNOSIS methods ,LONGITUDINAL method ,DEPRESSION in adolescence ,DIAGNOSIS ,COGNITION disorders ,DEMENTIA ,MENTAL depression ,HIPPOCAMPUS (Brain) ,DIGITAL image processing ,MAGNETIC resonance imaging ,RESEARCH funding ,DISEASE progression ,GERIATRIC Depression Scale - Abstract
Previous studies have highlighted that decreased hippocampal volume, an early neural correlate of dementia, is commonly observed in patients with mild cognitive impairment (MCI). However, it is unclear whether neurodegenerative and resultant clinical trajectories are accelerated in MCI patients with concomitant depressive symptoms, leading to a faster conversion to dementia stages than those who are not depressed. No longitudinal study has investigated whether depressed amnestic MCI (DEP+aMCI) patients show an earlier onset of progression to dementia than non-depressed amnestic MCI (DEP-aMCI) patients and whether progressive hippocampal volume reductions are related in the conversion process. Using data from Alzheimer's Disease Neuroimaging Initiative, we examined 2-year follow-up data from 38 DEP+aMCI patients and 38 matched DEP-aMCI patients and compared their ages of conversion from aMCI to AD and trajectories of progressive hippocampal volume changes. DEP+ and DEP- patients were defined as having baseline Geriatric Depression Scale scores of 5 or above and 0, respectively. DEP+ converters showed earlier ages of conversion to dementia (p = 0.009) and greater left hippocampal volume loss than both DEP- converters and DEP+ non-converters over the 2-year period (p = 0.003, p = 0.001, respectively). These findings could not be explained by changes in total brain volume, differences in their clinical symptoms of dementia, daily functioning, or apolipoprotein E4 genotypes. No difference in conversion rate to dementia or progressive hippocampal volume change was found between DEP+ patients and DEP-patients, which suggested depressive symptoms themselves may not lead to progression of dementia from MCI. In conclusion, there is a synergistic effect of depressive symptoms and smaller left hippocampal volume in MCI patients that accelerates conversion to dementia. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.